AmacaThera Partners with Leading Pharma for Innovative Single-Injection Biologic Development
AmacaThera, a clinical-stage biotech firm, has embarked on an ambitious project in partnership with a prominent global pharmaceutical company. This collaboration aims to develop a pioneering biologic that utilizes AmacaThera's advanced hydrogel delivery platform, named AmacaGel™. The goal is to produce a single-injection product that offers extended therapeutic effects, thereby enhancing patient outcomes. This initiative is co-funded by both organizations, allowing them to leverage their respective areas of expertise and resources to expedite the development process.
Molly Shoichet, Chief Scientific Officer of AmacaThera, expressed her excitement about this endeavor. She stated, "This partnership enables us to combine AmacaThera's extensive experience in drug delivery with the capabilities of our pharmaceutical ally. Our core technology has undergone rigorous validation at AmacaThera and at the University of Toronto across a spectrum of therapies, including small molecules and biologics."
The announcement comes on the heels of promising data from Phase 1 clinical trials demonstrating the effectiveness of AmacaGel™ when used in conjunction with an anesthetic. This initial human study not only validated the hydrogel platform but also provided critical insights regarding its compatibility with therapeutic agents.
Mike Cooke, CEO of AmacaThera, highlighted how this collaboration builds on the company's expertise and the human data gathered from previous trials. "This collaboration is based on our manufacturing capabilities and the valuable human data we have accumulated. It positions us to swiftly develop effective solutions to address the complexities associated with injection administration. The current landscape of hydrogels has been extensively tested, but what sets our platform apart is its high compatibility with various pharmaceutical modalities, a straightforward and scalable manufacturing process, and real-world human data."
The partnership has been facilitated through CQDM's Connect-Pharma series, which bridges Canadian companies and academia with global pharmaceutical members of CQDM. CQDM, a non-profit organization, is dedicated to fostering collaboration and innovation within the biopharmaceutical sector. Raphael Hofstein, a board member of CQDM, shared his enthusiasm about observing AmacaThera's trajectory from laboratory innovation to human testing. "This collaboration further emphasizes the industry's strong confidence in the AmacaThera platform."
Mark Steedman, Senior Director of Business Development at CQDM, noted, "We're thrilled to have formalized this collaboration and believe that AmacaThera's low-risk technology will enable this project to progress rapidly, yielding valuable data in a short timeframe."
Founded with the mission to address pressing challenges in therapeutic drug administration, AmacaThera is focused on advanced hydrogel formulations for sustained drug release. Their flagship platform, AmacaGel™, is designed to delivery extended therapies while minimizing systemic side effects. This innovative approach is particularly relevant in key therapeutic areas such as pain management and oncology.
The proprietary AmacaGel™ technology comprises two well-established polymers that form a fast-gelling hydrogel. Upon conventional syringe administration, it liquefies under shearing forces and promptly forms a depot at body temperature. Central to this platform, AMT-143 is a non-opioid local anesthetic that capitalizes on AmacaGel™ technology to offer long-lasting postoperative pain relief.
For more details on AmacaThera and its projects, please visit their website: www.amacathera.com.
As for CQDM, it operates as a non-profit consortium supporting collaborative R&D among stakeholders to transform innovative technologies into solutions addressing unmet medical needs, thus generating significant economic benefits for Quebec and Canada. Additional information can be found at www.cqdm.org and on their social media platforms.
Molly Shoichet, Chief Scientific Officer of AmacaThera, expressed her excitement about this endeavor. She stated, "This partnership enables us to combine AmacaThera's extensive experience in drug delivery with the capabilities of our pharmaceutical ally. Our core technology has undergone rigorous validation at AmacaThera and at the University of Toronto across a spectrum of therapies, including small molecules and biologics."
The announcement comes on the heels of promising data from Phase 1 clinical trials demonstrating the effectiveness of AmacaGel™ when used in conjunction with an anesthetic. This initial human study not only validated the hydrogel platform but also provided critical insights regarding its compatibility with therapeutic agents.
Mike Cooke, CEO of AmacaThera, highlighted how this collaboration builds on the company's expertise and the human data gathered from previous trials. "This collaboration is based on our manufacturing capabilities and the valuable human data we have accumulated. It positions us to swiftly develop effective solutions to address the complexities associated with injection administration. The current landscape of hydrogels has been extensively tested, but what sets our platform apart is its high compatibility with various pharmaceutical modalities, a straightforward and scalable manufacturing process, and real-world human data."
The partnership has been facilitated through CQDM's Connect-Pharma series, which bridges Canadian companies and academia with global pharmaceutical members of CQDM. CQDM, a non-profit organization, is dedicated to fostering collaboration and innovation within the biopharmaceutical sector. Raphael Hofstein, a board member of CQDM, shared his enthusiasm about observing AmacaThera's trajectory from laboratory innovation to human testing. "This collaboration further emphasizes the industry's strong confidence in the AmacaThera platform."
Mark Steedman, Senior Director of Business Development at CQDM, noted, "We're thrilled to have formalized this collaboration and believe that AmacaThera's low-risk technology will enable this project to progress rapidly, yielding valuable data in a short timeframe."
Founded with the mission to address pressing challenges in therapeutic drug administration, AmacaThera is focused on advanced hydrogel formulations for sustained drug release. Their flagship platform, AmacaGel™, is designed to delivery extended therapies while minimizing systemic side effects. This innovative approach is particularly relevant in key therapeutic areas such as pain management and oncology.
The proprietary AmacaGel™ technology comprises two well-established polymers that form a fast-gelling hydrogel. Upon conventional syringe administration, it liquefies under shearing forces and promptly forms a depot at body temperature. Central to this platform, AMT-143 is a non-opioid local anesthetic that capitalizes on AmacaGel™ technology to offer long-lasting postoperative pain relief.
For more details on AmacaThera and its projects, please visit their website: www.amacathera.com.
As for CQDM, it operates as a non-profit consortium supporting collaborative R&D among stakeholders to transform innovative technologies into solutions addressing unmet medical needs, thus generating significant economic benefits for Quebec and Canada. Additional information can be found at www.cqdm.org and on their social media platforms.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.